Short answer · Medically reviewed summary · Last updated: 2026-04-07
TL;DR: Cowden syndrome is a rare genetic disorder characterized by the development of multiple noncancerous growths called hamartomas and a significantly increased lifetime risk of developing certain types of cancer. It is part of a group of conditions known as PTEN hamartoma tumor syndrome (PHTS), which are caused by mutations in the PTEN gene. What is Cowden syndrome and how does it affect the body? Cowden syndrome is a multisystem condition that can affect almost any organ in the body.
TL;DR: Cowden syndrome is a rare genetic disorder characterized by the development of multiple noncancerous growths called hamartomas and a significantly increased lifetime risk of developing certain types of cancer. It is part of a group of conditions known as PTEN hamartoma tumor syndrome (PHTS), which are caused by mutations in the PTEN gene.
Cowden syndrome is a multisystem condition that can affect almost any organ in the body. The hallmark of Cowden syndrome is the formation of hamartomas—benign, tumor-like malformations made of cells that are normal for the tissue where they grow, but which have organized into a disorganized mass. These growths frequently appear on the skin, in the mouth, and within the gastrointestinal tract. Because Cowden syndrome disrupts the body’s natural tumor-suppression mechanisms, individuals have an elevated risk of developing cancers, particularly in the breast, thyroid, endometrium, kidney, and colon.
Cowden syndrome is caused by a germline mutation in the PTEN gene, which provides instructions for making a protein that acts as a tumor suppressor. This protein normally regulates cell division and prevents cells from growing or dividing too rapidly or in an uncontrolled way. When PTEN is mutated, the body loses this "brake" on cell growth, leading to the development of hamartomas and increasing the risk of malignancy. Cowden syndrome is inherited in an autosomal dominant pattern, meaning a person only needs one copy of the mutated gene from one parent to be affected.
While the exact prevalence of Cowden syndrome is difficult to determine because many cases remain undiagnosed or misdiagnosed, it is estimated to occur in approximately 1 in 200,000 people. However, some clinical researchers believe this number may be an underestimate. Within our community at DiseaseMaps.org, 116 people with Cowden syndrome have joined to share their experiences, highlighting the importance of patient-led data in rare disease research. The condition affects both men and women equally and does not show any specific geographic or ethnic predilection.
Diagnosis is often based on the Cleveland Clinic clinical diagnostic criteria, which assess the presence of specific "pathognomonic" signs. Common features include:
Cowden syndrome is the most widely recognized form of PTEN hamartoma tumor syndrome (PHTS). It is distinguished from other PHTS conditions—such as Bannayan-Riley-Ruvalcaba syndrome—by its specific clinical presentation and higher risk profile for certain malignancies. While other syndromes may share symptoms like macrocephaly or lipomas, Cowden syndrome is clinically defined by its high predisposition to epithelial cancers. Genetic testing is the gold standard for confirming the diagnosis and differentiating it from other genetic overgrowth syndromes.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.